Table 1

 Patient, disease, and treatment characteristics in 38 patients treated with methylprednisolone (MP) and in the three subgroups: no concomitant oral prednisolone treatment, with concomitant oral prednisolone treatment, and patients treated with antiresorptive osteoporosis treatment (ART)

All patients (n = 38)No concomitant oral prednisolone (n = 14)Concomitant oral prednisolone (n = 16)ART (n = 8)p Value
Values for continuous variables are given as mean (SD) and/or median (range). Numbers (%) for counts.
BMI, body mass index; ESR, erythrocyte sedimentation rate; CRP, C reactive protein; ART, antiresorptive treatment; RA, rheumatoid arthritis, SLE, systemic lupus erythematosus
Demographics
Age (years)48.4 (16.3)53.9 (14.2)39.6 (13.0)56.4 (18.8)0.13
Women, No (%)30 (79)11 (79)11 (69)8 (100)0.21
BMI (kg/m2)24.9 (5.1)25.3 (4.2)24.3 (5.8)25.3 (5.4)0.83
Caucasian, No (%)33 (87)12 (86)13 (81)8 (100)0.61
Disease characteristics
Disease duration (years)3.2 (0.1–40.0)4.0 (0.1–29.9)1.5 (0.1–29.0)4.9 (0.1–40.0)0.46
Diagnosis, No (%)
    SLE10 (26)0 (0)8 (50)2 (25)0.01
    Systemic sclerosis12 (32)9 (64)0 (0%)3 (38)
    Wegener’s granulomatosis4 (11)1 (7)2 (13)1 (13)
    RA6 (16)3 (21)2 (13)1 (13)
    Miscellaneous6 (16)1 (7)4 (25)1 (13)
Main indication for treatment, No (%)
    Lung disease19 (50)9 (64)3 (19)7 (88)0.04
    Kidney disease4 (11)0 (0)4 (25)0 (0)
    CNS involvement2 (5)1 (7)1 (6)0 (0)
    Vasculitis6 (16)2 (14)4 (25)0 (0)
    Resistant RA2 (5.3)1 (7)0 (0)1 (13)
    Miscellaneous5 (13)1 (7)4 (25)0 (0)
Months at follow up5.7 (2.3–33.7)4.2 (2.6–11.5)7.2 (2.3–33.7)13.8 (3.3–29.2)0.03
Mean ESR during follow up (mm/1st h)13.8 (0–49.3)18.5 (0–43.12)11.7 (2.4–48.7)6.1 (1.1–49.3)0.49
Mean CRP during follow up (mg/l)10.4 (5.0–108.5)9.7 (5.0–82.3)9.5 (5.0–44.1)11.6 (5.7–108.5)0.42
Anti-inflammatory treatment during follow up
Number of MP pulses5.7 (2.0)5.86 (1.66)5.5 (2.5)5.6 (1.5)0.89
Cumulative MP dose (mg)2969 (1612)3521 (1581)2617 (1347))2706 (2056)0.28
3050 (600–7110)3430 (1006–7110)2625 (630–5000)2360 (600–6480)
Average MP dose (mg)536 (230)598 (179)510 (240)475 (297)0.43
Oral predisolone treatment, No (%)20 (53)016 (100)4 (50)
Cumulative predisolone dose (mg)3450 (980–15150)04332 (4220)3980 (635)
3349 (980–15150)4313 (3248–4380)
Oral prednisolone (mg/day)10.0 (5.0–35.0)010.0 (5.0–35.0)7.5 (5.0–7.5)
Cumulative exposure to corticosteroid as equivalent prednisolone dose (mg)5850 (3722)4401 (1977)7604 (4460)4875 (3322)0.04
5234 (1258–18588)4288 (1258–8888)6480 (1823–18588)3999 (1813–12413)
Daily exposure to corticosteroid as equivalent prednisolone dose (mg/day)27.4 (16.3) 23.9 (5.9–76.2)31.1 (13.7) 29.5 (9.5–50.5)30.9 (18.8) 27.8 (11.6–76.2)13.9 (6.0) 14.4 (5.9–21.9)0.03
Cyclophosphamide at follow up, No (%)34 (89)12 (86)15 (94)7 (88)0.76
Osteoporosis treatment during follow up
ART, No (%)8 (21)0 (0)0 (0)8 (100)
    Oestrogen33
    Bisphosphonates55
Calcium alone, No (%)4 (11)0 (0)0 (0)4 (50)0.00
Calcium and vitamin D, No (%)11 (29)2 (14)7 (44)2 (25)0.20